Beatrice Southby Goad,Jill Rodda,Meagan Allen,Daniel Bamborschke,Isabella Overmars,Rachel J Kerr,Ittai Bushlin,Saurabh Chopra,Rohini Coorg,Gabriel Dabscheck,Jeremy L Freeman,Mark T Mackay,Orrin Devinsky,Renzo Guerrini,Elena Parrini,Bigna Bölsterli,Inna Hughes,Linda L Huh,Mahesh Kamate,Abby B Kunz,Gia Melikishvili,Christina Miteff,Kenneth Alexis Myers,Heather E Olson,Annapurna Poduri,Sekhar Pillai,Catherine Kate Riney,Adriane Sinclair,Sophie Calvert,Thomas Q Reynolds,Ana Roche Martinez,Angelo Russo,Lynette Grant Sadleir,Iciar Sanchez-Albisua,Stefano Sartori,Stephanie Shea,Constance L Smith-Hicks,Claire G Spooner,Rhys H Thomas,Simone L Ardern-Holmes,Richard Ian Webster,Massimiliano Valeriani,Pierangelo Veggiotti,Silvia Masnada,Tyson L Ware,Michael Yoong,Geza Berecki,Angela De Dominicis,Nicola Specchio,Marina Trivisano,Rikke Steensbjerre Møller,Markus Wolff,Walid Fazeli,Ingrid Scheffer,Katherine B Howell
{"title":"Development and Adaptive Function in Individuals With SCN2A-Related Disorders.","authors":"Beatrice Southby Goad,Jill Rodda,Meagan Allen,Daniel Bamborschke,Isabella Overmars,Rachel J Kerr,Ittai Bushlin,Saurabh Chopra,Rohini Coorg,Gabriel Dabscheck,Jeremy L Freeman,Mark T Mackay,Orrin Devinsky,Renzo Guerrini,Elena Parrini,Bigna Bölsterli,Inna Hughes,Linda L Huh,Mahesh Kamate,Abby B Kunz,Gia Melikishvili,Christina Miteff,Kenneth Alexis Myers,Heather E Olson,Annapurna Poduri,Sekhar Pillai,Catherine Kate Riney,Adriane Sinclair,Sophie Calvert,Thomas Q Reynolds,Ana Roche Martinez,Angelo Russo,Lynette Grant Sadleir,Iciar Sanchez-Albisua,Stefano Sartori,Stephanie Shea,Constance L Smith-Hicks,Claire G Spooner,Rhys H Thomas,Simone L Ardern-Holmes,Richard Ian Webster,Massimiliano Valeriani,Pierangelo Veggiotti,Silvia Masnada,Tyson L Ware,Michael Yoong,Geza Berecki,Angela De Dominicis,Nicola Specchio,Marina Trivisano,Rikke Steensbjerre Møller,Markus Wolff,Walid Fazeli,Ingrid Scheffer,Katherine B Howell","doi":"10.1212/wnl.0000000000213868","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND OBJECTIVES\r\nDevelopmental impairment is common in individuals with SCN2A-related disorders, although descriptions are limited. We aimed to determine trajectories and outcomes of development and adaptive function.\r\n\r\nMETHODS\r\nThis was a mixed retrospective cross-sectional study of individuals from an international SCN2A Natural History Study, who had neurologic/neurodevelopmental disorders due to an SCN2A variant. Individuals with SCN2A intragenic variants were grouped into early-onset (EO) and late-onset (LO) phenotypic groups; those with SCN2A-containing 2q24.3 copy number variants (CNVs) were considered separately. We collected medical and developmental history from parents/caregivers and medical records. Adaptive function and behavior were characterized using functional classification system levels and Vineland Adaptive Behavior Scales-3 (VABS-3) Parent/Caregiver Form. We repeated analyses on individuals with variants known to result in gain-of-function (GOF, typically EO phenotypes) or loss-of-function (LOF, typically LO phenotypes).\r\n\r\nRESULTS\r\nA total of 100 individuals (age 0.1-21.9 years, 39% female) were studied. Phenotypic groups were EO (n = 44), LO (n = 48), and 2q24.3 CNV (n = 8). Developmental delay/intellectual disability was present in 91 of 100, and 23 of 80 individuals (29%) older than 2 years had autism spectrum disorder. Of people older than the typical age for skill attainment, 59 of 95 (62%) could sit and 48 of 88 (55%) could walk. In addition, 27 of 86 individuals (31%) spoke more than 1-5 single words, and 24 of 74 (32%) followed two-step commands. Median VABS-3 Adaptive Behavior Composite (ABC) scores were as follows: the EO phenotypic group had a score of 56 (range 21-110), the LO phenotypic group had a score of 45 (range 20-89), and 5 of 6 with a 2q24.3 CNV had an ABC score of <45. The EO phenotypic group had 3 distinct subgroups, consistent with \"benign,\" \"intermediate,\" and \"severe\" definitions previously published. The LO phenotypic group showed a continuum of severity, without distinct clusters. However, clinically relevant differences in motor function were evident when subgrouped by seizure-onset age; a lower proportion with earlier seizure onset (age <18 months) were independently ambulant than those with later onset or no seizures (5/15 [33%] vs 10/12 [83%] vs 14/15 [93%], p < 0.01). Analyses of individuals with confirmed GOF/LOF variants (n = 57) showed similar results to the EO/LO analyses.\r\n\r\nDISCUSSION\r\nThe spectrum of developmental impairments and adaptive function in SCN2A-related disorders is extremely broad. Phenotypic subgroups provide prognostic information and critically inform clinical trial design.","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"282 1","pages":"e213868"},"PeriodicalIF":8.5000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/wnl.0000000000213868","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND AND OBJECTIVES
Developmental impairment is common in individuals with SCN2A-related disorders, although descriptions are limited. We aimed to determine trajectories and outcomes of development and adaptive function.
METHODS
This was a mixed retrospective cross-sectional study of individuals from an international SCN2A Natural History Study, who had neurologic/neurodevelopmental disorders due to an SCN2A variant. Individuals with SCN2A intragenic variants were grouped into early-onset (EO) and late-onset (LO) phenotypic groups; those with SCN2A-containing 2q24.3 copy number variants (CNVs) were considered separately. We collected medical and developmental history from parents/caregivers and medical records. Adaptive function and behavior were characterized using functional classification system levels and Vineland Adaptive Behavior Scales-3 (VABS-3) Parent/Caregiver Form. We repeated analyses on individuals with variants known to result in gain-of-function (GOF, typically EO phenotypes) or loss-of-function (LOF, typically LO phenotypes).
RESULTS
A total of 100 individuals (age 0.1-21.9 years, 39% female) were studied. Phenotypic groups were EO (n = 44), LO (n = 48), and 2q24.3 CNV (n = 8). Developmental delay/intellectual disability was present in 91 of 100, and 23 of 80 individuals (29%) older than 2 years had autism spectrum disorder. Of people older than the typical age for skill attainment, 59 of 95 (62%) could sit and 48 of 88 (55%) could walk. In addition, 27 of 86 individuals (31%) spoke more than 1-5 single words, and 24 of 74 (32%) followed two-step commands. Median VABS-3 Adaptive Behavior Composite (ABC) scores were as follows: the EO phenotypic group had a score of 56 (range 21-110), the LO phenotypic group had a score of 45 (range 20-89), and 5 of 6 with a 2q24.3 CNV had an ABC score of <45. The EO phenotypic group had 3 distinct subgroups, consistent with "benign," "intermediate," and "severe" definitions previously published. The LO phenotypic group showed a continuum of severity, without distinct clusters. However, clinically relevant differences in motor function were evident when subgrouped by seizure-onset age; a lower proportion with earlier seizure onset (age <18 months) were independently ambulant than those with later onset or no seizures (5/15 [33%] vs 10/12 [83%] vs 14/15 [93%], p < 0.01). Analyses of individuals with confirmed GOF/LOF variants (n = 57) showed similar results to the EO/LO analyses.
DISCUSSION
The spectrum of developmental impairments and adaptive function in SCN2A-related disorders is extremely broad. Phenotypic subgroups provide prognostic information and critically inform clinical trial design.
期刊介绍:
Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology.
As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content.
Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.